Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia

Published:2020-07-18 Issue:9 Volume:99 Page:1989-2007
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Megías-Vericat Juan Eduardo^ORCID,Solana-Altabella Antonio,Ballesta-López Octavio^ORCID,Martínez-Cuadrón David,Montesinos Pau^ORCID

Funder

Instituto de Salud Carlos III

Fundación para la Investigación del Hospital Universitari La Fe

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-020-04186-0.pdf

Reference70 articles.

1. Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, Mannis G, Marcucci G, Martin MG, Mims A, O'Donnell MR, Olin R, Peker D, Perl A, Pollyea DA, Pratz K, Prebet T, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wieduwilt M, Gregory KM, OCN, Hammond L, Ogba N (2019) Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 17(6):721–749

2. Medeiros BC, Chan SM, Daver NG, Jonas BA, Pollyea DA (2019) Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. Am J Hematol 94(7):803–811

3. Megías-Vericat JE, Ballesta-López O, Barragán E, Martínez-Cuadrón D, Montesinos P (2020) Tyrosine kinase inhibitors for acute myeloid leukemia: a step toward disease control? Blood Rev:100675 [Epub ahead of print]

4. Megías-Vericat JE, Ballesta-López O, Barragán E, Montesinos P (2019) IDH1-mutated relapsed or refractory AML: current challenges and future prospects. Blood Lymphat Cancer 9:19–32

5. Pollyea DA, Amaya M, Strati P, Konopleva MY (2019) Venetoclax for AML: changing the treatment paradigm. Blood Adv 3(24):4326–4335

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipopolymer/siRNA Complexes Engineered for Optimal Molecular and Functional Response with Chemotherapy in FLT3-Mutated Acute Myeloid Leukemia;Acta Biomaterialia;2024-09

2. Individualized medication of venetoclax based on therapeutic drug monitoring in Chinese acute myeloid leukemia patients using an HPLC method;Anti-Cancer Drugs;2024-07-08

3. FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia;Cancer Letters;2024-06

4. An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021);Anti-Cancer Agents in Medicinal Chemistry;2024-05

5. Triazole antifungal drug interactions—practical considerations for excellent prescribing;Journal of Antimicrobial Chemotherapy;2024-04-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3